

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Credelio 56 mg chewable tablets for dogs (1.3-2.5 kg)  
Credelio 112 mg chewable tablets for dogs (>2.5-5.5 kg)  
Credelio 225 mg chewable tablets for dogs (>5.5-11 kg)  
Credelio 450 mg chewable tablets for dogs (>11-22 kg)  
Credelio 900 mg chewable tablets for dogs (>22-45 kg)

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

### Active substance:

Each chewable tablet contains:

Credelio chewable tablets	lotilaner (mg)
for dogs (1.3-2.5 kg)	56.25
for dogs (>2.5-5.5 kg)	112.5
for dogs (>5.5-11 kg)	225
for dogs (>11-22 kg)	450
for dogs (>22-45 kg)	900

### Excipients:

Qualitative composition of excipients and other constituents
Cellulose, powdered
Lactose monohydrate
Silicified microcrystalline cellulose
Meat dry flavour
Crospovidone
Povidone K30
Sodium laurilsulfate
Silica, colloidal anhydrous
Magnesium stearate

White to beige round chewable tablets with brownish spots.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Dogs

### 3.2 Indications for use for each target species

For the treatment of flea and tick infestations in dogs.

This veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas (*Ctenocephalides felis* and *C. canis*) and ticks (*Rhipicephalus sanguineus*, *Ixodes ricinus*, *I. hexagonus* and *Dermacentor reticulatus*).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

For reduction of the risk of infection with *Babesia canis canis* via transmission by *Dermacentor reticulatus* for one month. The effect is indirect due to the activity of the veterinary medicinal product against the vector.

For the treatment of demodicosis (caused by *Demodex canis*).

For the treatment of sarcoptic mange (*Sarcoptes scabiei* var. *canis*).

### **3.3 Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### **3.4 Special warnings**

Parasites need to start feeding on the host to become exposed to lotilaner; therefore, the risk of the transmission of parasite borne diseases cannot be completely excluded. Specifically, as an acaricidal effect against *D. reticulatus* may take up to 48 hours, transmission of *B. canis canis* during the first 48 hours cannot be excluded.

### **3.5 Special precautions for use**

#### Special precautions for safe use in the target species:

All safety and efficacy data have been acquired from dogs and puppies 8 weeks of age and older and 1.3 kg of body weight and greater. Use of this veterinary medicinal product in puppies younger than 8 weeks of age or less than 1.3 kg of body weight should be based on a benefit-risk assessment by the responsible veterinarian.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after handling the product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

#### Special precautions for the protection of the environment:

Not applicable.

### **3.6 Adverse events**

Dogs:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Diarrhoea <sup>1,2</sup> , Bloody diarrhoea <sup>1</sup> , Vomiting <sup>1,2</sup> ; Anorexia <sup>1,2</sup> , Lethargy <sup>2</sup> , Polydipsia <sup>1,2</sup> ; Ataxia <sup>3</sup> , Convulsion <sup>3</sup> , Tremor <sup>3</sup> ; Pruritus <sup>1,2</sup> ; Inappropriate urination <sup>1</sup> , Polyuria <sup>1,2</sup> , Urinary incontinence <sup>1,2</sup>
--	---

<sup>1</sup> Mild and transient

<sup>2</sup> Typically resolve without treatment

<sup>3</sup> Transient in most cases

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during pregnancy, lactation or in breeding dogs.

#### Pregnancy and lactation:

Use only according to the benefit/risk assessment by the responsible veterinarian.

Laboratory studies in rats have not produced any evidence of teratogenic effects or any adverse effect on the reproductive capacity of males and females.

### **3.8 Interaction with other medicinal products and other forms of interaction**

None known.

During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed.

### **3.9 Administration routes and dosage**

For oral use.

The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 20 to 43 mg lotilaner/kg bodyweight.

Body weight of dog (kg)	Strength and number of tablets to be administered				
	Credelio 56 mg	Credelio 112 mg	Credelio 225 mg	Credelio 450 mg	Credelio 900 mg
1.3-2.5	1				
>2.5-5.5		1			
>5.5-11.0			1		
>11.0-22.0				1	
>22.0-45.0					1
>45	Appropriate combination of tablets				

Use an appropriate combination of available strengths to achieve the recommended dose of 20-43 mg/kg.

Credelio is a palatable chewable flavoured tablet. Administer the chewable tablet(s) monthly with or after food.

For the treatment of demodicosis (caused by *Demodex canis*):

Monthly administration of the product for two consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until two negative skin scrapings are obtained one month apart. Severe cases may require prolonged monthly treatments. As demodicosis is

a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

For the treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*):  
Monthly administration of the product for two consecutive months. Further monthly administration of the product may be required based on clinical assessment and skin scrapings.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

No adverse reactions were observed following oral administration to puppies aged 8-9 weeks and weighing 1.3-3.6 kg treated with overdoses of up to 5 times the maximum recommended dose (43 mg, 129 mg and 215 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Not applicable.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code :**

QP53BE04

### **4.2 Pharmacodynamics**

Lotilaner, a pure enantiomer from the isoxazoline class is active against fleas (*Ctenocephalides felis* and *Ctenocephalides canis*), - the tick species *Dermacentor reticulatus*, *Ixodes hexagonus*, *Ixodes ricinus* and *Rhipicephalus sanguineus* as well as *Demodex canis* and *Sarcoptes scabiei* var. *canis* mites.

Lotilaner is a potent inhibitor of gamma-aminobutyric acid (GABA)-gated chloride channels, resulting in rapid death of ticks and fleas. The activity of lotilaner was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin).

For fleas, the onset of efficacy is within 4 hours of attachment for one month after product administration. Fleas on the animal prior to administration are killed within 6 hours.

For ticks, the onset of efficacy is within 48 hours of attachment for one month after product administration. Existing *I. ricinus* ticks on the animal prior to administration are killed within 8 hours.

The veterinary medicinal product kills existing and newly emerged fleas on dogs before they can lay eggs. Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the dog has access.

### **4.3 Pharmacokinetics**

Following oral administration, lotilaner is readily absorbed and peak blood concentration is reached within 2 hours. Food enhances the absorption. The terminal half-life is approximately 4 weeks. This long terminal half-life provides effective blood concentrations for the entire duration of the inter-dosing interval.

The major route of elimination is biliary excretion and renal excretion is the minor route of elimination (less than 10% of the dose). Lotilaner is metabolized to a small extent into more hydrophilic compounds which are observed in faeces and urine.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Not applicable.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

### **5.3 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **5.4 Nature and composition of immediate packaging**

The tablets are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. Each tablet strength is available in pack sizes of 1, 3, 6 or 18 tablets.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Elanco GmbH

## **7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/17/206/001-015

EU/2/17/206/024-028

## **8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 25/04/2017

## **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{DD/MM/YYYY}

## **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>)

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Credelio 12 mg chewable tablets for cats (0.5-2.0 kg)  
Credelio 48 mg chewable tablets for cats (>2.0-8.0 kg)

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

### Active substance:

Each chewable tablet contains:

Credelio chewable tablets	lotilaner (mg)
for cats (0.5-2.0 kg)	12
for cats (>2.0-8.0 kg)	48

### Excipients:

Qualitative composition of excipients and other constituents
Yeast powder (flavour)
Silicified microcrystalline cellulose
Cellulose, powdered
Lactose monohydrate
Povidone K30
Crospovidone
Sodium laurilsulfate
Vanillin (flavour)
Silica, colloidal anhydrous
Magnesium stearate

White to brownish round chewable tablets with brownish spots.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Cats

### 3.2 Indications for use for each target species

For the treatment of flea and tick infestations on cats.

This veterinary medicinal product provides immediate and persistent killing activity for 1 month against fleas (*Ctenocephalides felis* and *C. canis*) and ticks (*Ixodes ricinus*).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

### **3.3 Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### **3.4 Special warnings**

Parasites need to start feeding on the host to become exposed to lotilaner; therefore, the risk of the transmission of parasite borne diseases cannot be completely excluded.

Acceptable levels of efficacy may not be achieved if the veterinary medicinal product is not administered with food or within 30 minutes after feeding.

Due to insufficient data to support efficacy against ticks in young cats, this product is not recommended for the treatment of ticks in kittens 5 months of age or younger.

### **3.5 Special precautions for use**

#### Special precautions for safe use in the target species:

Safety and efficacy data has been studied in cats aged 8 weeks and older with a body weight of 0.5 kg or more. Therefore, use of this veterinary medicinal product in kittens younger than 8 weeks of age or less than 0.5 kg of body weight should be based on a benefit-risk assessment by the responsible veterinarian.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after handling the product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

#### Special precautions for the protection of the environment:

Not applicable.

### **3.6 Adverse events**

Cats:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Hyperactivity <sup>1,2</sup> Vomiting <sup>2</sup> Ataxia, Muscle tremor Tachypnoea Pruritus <sup>1,2</sup> Anorexia, Lethargy
--	---

<sup>1</sup>Mild and transient

<sup>2</sup>Typically resolves without treatment

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during pregnancy or lactation.

#### Pregnancy and lactation:

Use only according to the benefit/risk assessment by the responsible veterinarian. Laboratory studies in rats have not produced any evidence of teratogenic effects, or any adverse effect on the reproductive capacity of males and females.

#### **3.8 Interaction with other medicinal products and other forms of interaction**

None known.

During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed.

#### **3.9 Administration routes and dosage**

For oral use.

The flavoured veterinary medicinal product should be administered in accordance with the following table to ensure a single dose of 6 to 24 mg lotilaner/kg bodyweight.

Body weight of cat (kg)	Strength and number of tablets to be administered	
	Credelio 12 mg	Credelio 48 mg
0.5-2.0	1	
>2.0-8.0		1
>8.0	Appropriate combination of tablets	

For cats of more than 8 kg body weight, use an appropriate combination of available strengths to achieve the recommended dose of 6–24 mg/kg.

Administer the veterinary medicinal product with food or within 30 minutes after feeding.

For optimal control of tick and flea infestations, the veterinary medicinal product should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations.

#### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

No adverse reactions were observed following oral administration to kittens aged 8 weeks, weighing 0.5 kg, which were treated with more than 5 times the maximum recommended dose (130 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals.

#### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

#### **3.12 Withdrawal periods**

Not applicable.

### **4. PHARMACOLOGICAL INFORMATION**

#### **4.1 ATCvet code : QP53BE04**

## 4.2 Pharmacodynamics

Lotilaner, a pure enantiomer from the isoxazoline class, is active against fleas (*Ctenocephalides felis* and *Ctenocephalides canis*) and ticks (*Ixodes ricinus*).

Lotilaner is a potent inhibitor of gamma-aminobutyric acid (GABA)-gated chloride channels, resulting in rapid death of ticks and fleas. In *in vitro* studies, the activity of lotilaner against some arthropod species was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin).

For fleas, the onset of efficacy is within 12 hours of attachment for one month after product administration. Fleas on the animal prior to administration are killed within 8 hours.

For ticks, the onset of efficacy is within 24 hours of attachment for one month after product administration. Existing ticks on the animal prior to administration are killed within 18 hours.

The veterinary medicinal product kills existing and newly emerged fleas on cats before they can lay eggs. Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the cat has access.

## 4.3 Pharmacokinetics

Following oral administration, lotilaner is readily absorbed and peak blood concentration is reached at 4 hours. Lotilaner is approximately 10 times more bioavailable when administered with food. The terminal half-life is approximately 4 weeks (harmonic mean). This terminal half-life provides effective blood concentrations for the entire duration of the inter-dosing interval.

The major route of elimination is biliary excretion, and renal excretion is the minor route of elimination (less than 10 % of the dose). Lotilaner is metabolized to a small extent into more hydrophilic compounds, which are observed in faeces and urine.

## 5. PHARMACEUTICAL PARTICULARS

### 5.1 Major incompatibilities

Not applicable.

### 5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

### 5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

### 5.4 Nature and composition of immediate packaging

The tablets are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. Each tablet strength is available in pack sizes of 1, 3, 6 or 18 tablets.

Not all pack sizes may be marketed.

### 5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Elanco GmbH

**7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/17/206/016-023

**8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 25/04/2017

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{DD/MM/YYYY}

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE****CARDBOARD BOX (DOGS)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Credelio 56 mg chewable tablets for dogs (1.3-2.5 kg)  
Credelio 112 mg chewable tablets for dogs (>2.5-5.5 kg)  
Credelio 225 mg chewable tablets for dogs (>5.5-11 kg)  
Credelio 450 mg chewable tablets for dogs (>11-22 kg)  
Credelio 900 mg chewable tablets for dogs (>22-45 kg)

**2. STATEMENT OF ACTIVE SUBSTANCES**

56 mg lotilaner  
112 mg lotilaner  
225 mg lotilaner  
450 mg lotilaner  
900 mg lotilaner

**3. PACKAGE SIZE**

1 tablet  
3 tablets  
6 tablets  
18 tablets

**4. TARGET SPECIES**

Dogs

**5. INDICATIONS****6. ROUTES OF ADMINISTRATION**

Oral use.

Administer with or after food.

**7. WITHDRAWAL PERIODS****8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS****10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"**

Read the package leaflet before use.

**11. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Elanco GmbH

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/17/206/001 (56 mg lotilaner; 1 chewable tablet)  
EU/2/17/206/002 (56 mg lotilaner; 3 chewable tablets)  
EU/2/17/206/003 (56 mg lotilaner; 6 chewable tablets)  
EU/2/17/206/024 (56 mg lotilaner; 18 chewable tablets)  
EU/2/17/206/004 (112 mg lotilaner; 1 chewable tablet)  
EU/2/17/206/005 (112 mg lotilaner; 3 chewable tablets)  
EU/2/17/206/006 (112 mg lotilaner; 6 chewable tablets)  
EU/2/17/206/025 (112 mg lotilaner; 18 chewable tablets)  
EU/2/17/206/007 (225 mg lotilaner; 1 chewable tablet)  
EU/2/17/206/008 (225 mg lotilaner; 3 chewable tablets)  
EU/2/17/206/009 (225 mg lotilaner; 6 chewable tablets)  
EU/2/17/206/026 (225 mg lotilaner; 18 chewable tablets)  
EU/2/17/206/010 (450 mg lotilaner; 1 chewable tablet)  
EU/2/17/206/011 (450 mg lotilaner; 3 chewable tablets)  
EU/2/17/206/012 (450 mg lotilaner; 6 chewable tablets)  
EU/2/17/206/027 (450 mg lotilaner; 18 chewable tablets)  
EU/2/17/206/013 (900 mg lotilaner; 1 chewable tablet)  
EU/2/17/206/014 (900 mg lotilaner; 3 chewable tablets)  
EU/2/17/206/015 (900 mg lotilaner; 6 chewable tablets)  
EU/2/17/206/028 (900 mg lotilaner; 18 chewable tablets)

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE****CARDBOARD BOX (CATS)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Credelio 12 mg chewable tablets for cats (0.5-2.0 kg)  
Credelio 48 mg chewable tablets for cats (>2.0-8.0 kg)

**2. STATEMENT OF ACTIVE SUBSTANCES**

12 mg lotilaner  
48 mg lotilaner

**3. PACKAGE SIZE**

1 tablet  
3 tablets  
6 tablets  
18 tablets

**4. TARGET SPECIES**

Cats

**5. INDICATIONS****6. ROUTES OF ADMINISTRATION**

Oral use.

Administer with food or within 30 minutes after feeding.

**7. WITHDRAWAL PERIODS****8. EXPIRY DATE**

Exp. {mm/yyyy}

**9. SPECIAL STORAGE PRECAUTIONS**

**10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"**

Read the package leaflet before use.

**11. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Elanco GmbH

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/17/206/016 (12 mg lotilaner; 1 chewable tablet)  
EU/2/17/206/017 (12 mg lotilaner; 3 chewable tablets)  
EU/2/17/206/018 (12 mg lotilaner; 6 chewable tablets)  
EU/2/17/206/022 (12 mg lotilaner; 18 chewable tablets)  
EU/2/17/206/019 (48 mg lotilaner; 1 chewable tablet)  
EU/2/17/206/020 (48 mg lotilaner; 3 chewable tablets)  
EU/2/17/206/021 (48 mg lotilaner; 6 chewable tablets)  
EU/2/17/206/023 (48 mg lotilaner; 18 chewable tablets)

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**BLISTERS (DOGS)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Credelio



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

56 mg lotilaner

112 mg lotilaner

225 mg lotilaner

450 mg lotilaner

900 mg lotilaner

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**BLISTERS (CATS)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Credelio



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

12 mg lotilaner

48 mg lotilaner

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Credelio 56 mg chewable tablets for dogs (1.3-2.5 kg)  
Credelio 112 mg chewable tablets for dogs (>2.5-5.5 kg)  
Credelio 225 mg chewable tablets for dogs (>5.5-11 kg)  
Credelio 450 mg chewable tablets for dogs (>11-22 kg)  
Credelio 900 mg chewable tablets for dogs (>22-45 kg)

### 2. Composition

Each chewable tablet contains:

Credelio chewable tablets	lotilaner (mg)
for dogs (1.3-2.5 kg)	56.25
for dogs (>2.5-5.5 kg)	112.5
for dogs (>5.5-11 kg)	225
for dogs (>11-22 kg)	450
for dogs (>22-45 kg)	900

White to beige round chewable tablets with brownish spots.

### 3. Target species

Dogs



### 4. Indications for use

Treatment of flea and tick infestations in dogs.

This veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas (*Ctenocephalides felis* and *C. canis*) and ticks (*Rhipicephalus sanguineus*, *Ixodes ricinus*, *I. hexagonus*, and *Dermacentor reticulatus*).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

For reduction of the risk of infection with *Babesia canis canis* via transmission by *Dermacentor reticulatus* for one month. The effect is indirect due to the activity of the veterinary medicinal product against the vector.

For the treatment of demodicosis (caused by *Demodex canis*).

For the treatment of sarcoptic mange (*Sarcoptes scabiei* var. *canis*).

## 5. Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

## 6. Special warnings

### Special warnings:

Parasites need to start feeding on the host to become exposed to lotilaner; therefore, the risk of the transmission of parasite borne diseases cannot be completely excluded. Specifically, as an acaricidal effect against *D. reticulatus* may take up to 48 hours, transmission of *B. canis canis* during the first 48 hours cannot be excluded.

### Special precautions for safe use in the target species:

All safety and efficacy data have been acquired from dogs and puppies 8 weeks of age and older and 1.3 kg of body weight and greater. The administration of this product in puppies younger than 8 weeks of age or less than 1.3 kg of body weight should be based on a benefit-risk assessment by the responsible veterinarian.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after handling the product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

### Pregnancy and lactation:

Laboratory studies in rats have not produced any evidence of teratogenic effects.

The safety of the veterinary medicinal product has not been established during pregnancy or lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

### Fertility:

Laboratory studies in rats have not produced any evidence of any adverse effect on the reproductive capacity of males and females.

The safety of the veterinary medicinal product has not been established in breeding dogs. Use only according to the benefit/risk assessment by the responsible veterinarian.

### Interaction with other medicinal products and other forms of interaction:

None known. During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed.

### Overdose:

No adverse reactions were observed following oral administration to puppies aged 8-9 weeks and weighing 1.3-3.6 kg treated with overdoses of up to 5 times the maximum recommended dose (43 mg, 129 mg and 215 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals.

## 7. Adverse events

### Dogs:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):
---

Diarrhoea <sup>1,2</sup> , Bloody diarrhoea <sup>1</sup> , Vomiting <sup>1,2</sup> ;
--

Anorexia<sup>1,2</sup>, Lethargy<sup>2</sup>, Polydipsia (increased thirst)<sup>1,2</sup>;  
 Ataxia<sup>3</sup>, Convulsion<sup>3</sup>, Tremor<sup>3</sup>;  
 Pruritus (itching)<sup>1,2</sup>;  
 Inappropriate urination<sup>1</sup>, Polyuria (increased urination)<sup>1,2</sup>, Urinary incontinence<sup>1,2</sup>

<sup>1</sup> Mild and transient

<sup>2</sup> Typically resolve without treatment

<sup>3</sup> Transient in most cases

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

## 8. Dosage for each species, routes and method of administration

For oral use.

The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 20 to 43 mg lotilaner/kg bodyweight.

Body weight of dog (kg)	Strength and number of tablets to be administered				
	Credelio 56 mg	Credelio 112 mg	Credelio 225 mg	Credelio 450 mg	Credelio 900 mg
1.3-2.5	1				
>2.5-5.5		1			
>5.5-11.0			1		
>11.0-22.0				1	
>22.0-45.0					1
>45	Appropriate combination of tablets				

Use an appropriate combination of available strengths to achieve the recommended dose of 20-43 mg/kg.

For the treatment of demodicosis (caused by *Demodex canis*):

Monthly administration of the product for two consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until two negative skin scrapings are obtained one month apart. Severe cases may require prolonged monthly treatments. As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

For the treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*):

Monthly administration of the product for two consecutive months. Further monthly administration of the product may be required based on clinical assessment and skin scrapings.

## 9. Advice on correct administration

Credelio is a palatable chewable flavoured tablet. Administer the chewable tablet(s) monthly with or after food.

## 10. Withdrawal periods

Not applicable.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister after Exp. The expiry date refers to the last day of that month.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. Marketing authorisation numbers and pack sizes**

EU/2/17/206/001-015

EU/2/17/206/024-028

The tablets are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. Each tablet strength is available in pack sizes of 1, 3, 6 or 18 tablets.

Not all pack sizes may be marketed.

## **15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

## **16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse events:

Elanco GmbH, Heinz-Lohmann-Str. 4, 27472 Cuxhaven, Germany

**België/Belgique/Belgien**  
Tél/Tel: +32 33000338

**Lietuva**  
Tel: +372 8840389

PV.BEL@elancoah.com

**Република България**  
Tel: +48 221047815  
PV.BGR@elancoah.com

**Česká republika**  
Tel: +420 228880231  
PV.CZE@elancoah.com

**Danmark**  
Tlf: +45 78775477  
PV.DNK@elancoah.com

**Deutschland**  
Tel: +49 32221852372  
PV.DEU@elancoah.com

**Eesti**  
Tel: +372 8807513  
PV.EST@elancoah.com

**Ελλάδα**  
Τηλ: +386 82880137  
PV.GRC@elancoah.com

**España**  
Tel: +34 518890402  
PV.ESP@elancoah.com

**France**  
Tél: +33 975180507  
PV.FRA@elancoah.com

**Hrvatska**  
Tel: +36 18088411  
PV.HRV@elancoah.com

**Ireland**  
Tel: +44 3308221732  
PV.IRL@elancoah.com

**Ísland**  
Sími: +45 89875379  
PV.ISL@elancoah.com

**Italia**  
Tel: +39 0282944231  
PV.ITA@elancoah.com

**Κύπρος**  
Τηλ: +386 82880096  
PV.CYP@elancoah.com

**Latvija**  
Tel: +372 8840390  
PV.LVA@elancoah.com

PV.LTU@elancoah.com

**Luxembourg/Luxemburg**  
Tél/Tel: +352 20881943  
PV.LUX@elancoah.com

**Magyarország**  
Tel.: +36 18506968  
PV.HUN@elancoah.com

**Malta**  
Tel: +36 18088530  
PV.MLT@elancoah.com

**Nederland**  
Tel: +31 852084939  
PV.NLD@elancoah.com

**Norge**  
Tlf: +47 81503047  
PV.NOR@elancoah.com

**Österreich**  
Tel: +43 720116570  
PV.AUT@elancoah.com

**Polska**  
Tel.: +48 221047306  
PV.POL@elancoah.com

**Portugal**  
Tel: +351 308801355  
PV.PRT@elancoah.com

**România**  
Tel: +40 376300400  
PV.ROU@elancoah.com

**Slovenija**  
Tel: +386 82880093  
PV.SVN@elancoah.com

**Slovenská republika**  
Tel: +420 228880231  
PV.SVK@elancoah.com

**Suomi/Finland**  
Puh/Tel: +358 753252088  
PV.FIN@elancoah.com

**Sverige**  
Tel: +46 108989397  
PV.SWE@elancoah.com

**United Kingdom (Northern Ireland)**  
Tel: +44 3308221732  
PV.XXI@elancoah.com

Manufacturer responsible for batch release:

Elanco France S.A.S., 26 rue de la Chapelle, 68330 Huningue, France

**17. Other information**

Lotilaner, a pure enantiomer from the isoxazoline class is active against fleas (*Ctenocephalides felis* and *Ctenocephalides canis*), - the tick species *Dermacentor reticulatus*, *Ixodes hexagonus*, *Ixodes ricinus* and *Rhipicephalus sanguineus* as well as *Demodex canis* and *Sarcoptes scabiei* var. *canis* mites.

Lotilaner is a potent inhibitor of gamma-aminobutyric acid (GABA)-gated chloride channels, resulting in rapid death of ticks and fleas. The activity of lotilaner was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin).

For fleas, the onset of efficacy is within 4 hours of attachment for one month after product administration. Fleas on the animal prior to administration are killed within 6 hours.

For ticks, the onset of efficacy is within 48 hours of attachment for one month after product administration. Existing *I. ricinus* ticks on the animal prior to administration are killed within 8 hours.

The veterinary medicinal product kills existing and newly emerged fleas on dogs before they can lay eggs. Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the dog has access.

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Credelio 12 mg chewable tablets for cats (0.5-2.0 kg)  
Credelio 48 mg chewable tablets for cats (>2.0-8.0 kg)

### 2. Composition

Each chewable tablet contains:

Credelio chewable tablets	lotilaner (mg)
for cats (0.5-2.0 kg)	12
for cats (>2.0-8.0 kg)	48

White to brownish round chewable tablets with brownish spots.

### 3. Target species

Cats



### 4. Indications for use

For the treatment of flea and tick infestations on cats.

This veterinary medicinal product provides immediate and persistent killing activity for 1 month against fleas (*Ctenocephalides felis* and *C. canis*) and ticks (*Ixodes ricinus*).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

### 5. Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### 6. Special warnings

#### Special warnings:

Parasites need to start feeding on the host to become exposed to lotilaner; therefore, the risk of the transmission of parasite borne diseases cannot be completely excluded.

Acceptable levels of efficacy may not be achieved if the veterinary medicinal product is not administered with food or within 30 minutes after feeding.

Due to insufficient data to support efficacy against ticks in young cats, this product is not recommended for the treatment of ticks in kittens 5 months of age or younger.

Special precautions for safe use in the target species:

All safety and efficacy data have been acquired from cats and kittens 8 weeks of age and older and 0.5 kg of body weight and greater. Use of this veterinary medicinal product in kittens younger than 8 weeks of age or less than 0.5 kg of body weight should be based on a benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after handling the product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Pregnancy and lactation:

Laboratory studies in rats have not produced any evidence of teratogenic effects.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

Fertility:

Laboratory studies in rats have not produced any evidence of any adverse effect on the reproductive capacity of males and females.

The safety of the veterinary medicinal product in breeding queens has not been established. Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

None known. During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed.

Overdose:

No adverse reactions were observed following oral administration to kittens aged 8 weeks and weighing 0.5 kg treated with overdoses of more than 5 times the maximum recommended dose rate (130 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals.

## 7. Adverse events

Cats:

*Very rare (<1 animal / 10 000 animals treated, including isolated reports):*

Hyperactivity<sup>1,2</sup>

Vomiting<sup>2</sup>

Ataxia (incoordination), Muscle tremor

Tachypnoea (rapid shallow breathing)

Pruritus (itching)<sup>1,2</sup>

Anorexia (loss of appetite), Lethargy

<sup>1</sup> Mild and transient

<sup>2</sup> Typically resolves without treatment

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

## **8. Dosage for each species, routes and method of administration**

For oral use.

The flavoured veterinary medicinal product should be administered in accordance with the following table to ensure a single dose of 6 to 24 mg lotilaner/kg bodyweight.

Body weight of cat (kg)	Strength and number of tablets to be administered	
	Credelio 12 mg	Credelio 48 mg
0.5-2.0	1	
>2.0-8.0		1
>8.0	Appropriate combination of tablets	

For cats of more than 8 kg body weight use an appropriate combination of available strengths to achieve the recommended dose of 6-24 mg/kg.

## **9. Advice on correct administration**

Administer the veterinary medicinal product with food or within 30 minutes after feeding.

For optimal control of tick and flea infestations, the veterinary medicinal product should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations

## **10. Withdrawal periods**

Not applicable.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister after Exp. The expiry date refers to the last day of that month.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived therefrom in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

### **14. Marketing authorisation numbers and pack sizes**

EU/2/17/206/016-023

The tablets are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. Each tablet strength is available in pack sizes of 1, 3, 6 or 18 tablets.

Not all pack sizes may be marketed.

### **15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

### **16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse events:

Elanco GmbH, Heinz-Lohmann-Str. 4, 27472 Cuxhaven, Germany

**België/Belgique/Belgien**  
Tél/Tel: +32 33000338  
PV.BEL@elancoah.com

**Lietuva**  
Tel: +372 8840389  
PV.LTU@elancoah.com

**Република България**  
Тел: +48 221047815  
PV.BGR@elancoah.com

**Luxembourg/Luxemburg**  
Tél/Tel: +352 20881943  
PV.LUX@elancoah.com

**Česká republika**  
Tel: +420 228880231  
PV.CZE@elancoah.com

**Magyarország**  
Tel.: +36 18506968  
PV.HUN@elancoah.com

**Danmark**  
Tlf: +45 78775477  
PV.DNK@elancoah.com

**Malta**  
Tel: +36 18088530  
PV.MLT@elancoah.com

**Deutschland**  
Tel: +49 32221852372  
PV.DEU@elancoah.com

**Nederland**  
Tel: +31 852084939  
PV.NLD@elancoah.com

**Eesti**  
Tel: +372 8807513  
PV.EST@elancoah.com

**Norge**  
Tlf: +47 81503047  
PV.NOR@elancoah.com

**Ελλάδα**  
Τηλ: +386 82880137  
PV.GRC@elancoah.com

**Österreich**  
Tel: +43 720116570  
PV.AUT@elancoah.com

**España**  
Tel: +34 518890402  
PV.ESP@elancoah.com

**France**  
Tél: +33 975180507  
PV.FRA@elancoah.com

**Hrvatska**  
Tel: +36 18088411  
PV.HRV@elancoah.com

**Ireland**  
Tel: +44 3308221732  
PV.IRL@elancoah.com

**Ísland**  
Sími: +45 89875379  
PV.ISL@elancoah.com

**Italia**  
Tel: +39 0282944231  
PV.ITA@elancoah.com

**Kύπρος**  
Τηλ: +386 82880096  
PV.CYP@elancoah.com

**Latvija**  
Tel: +372 8840390  
PV.LVA@elancoah.com

**Polska**  
Tel.: +48 221047306  
PV.POL@elancoah.com

**Portugal**  
Tel: +351 308801355  
PV.PRT@elancoah.com

**România**  
Tel: +40 376300400  
PV.ROU@elancoah.com

**Slovenija**  
Tel: +386 82880093  
PV.SVN@elancoah.com

**Slovenská republika**  
Tel: +420 228880231  
PV.SVK@elancoah.com

**Suomi/Finland**  
Puh/Tel: +358 753252088  
PV.FIN@elancoah.com

**Sverige**  
Tel: +46 108989397  
PV.SWE@elancoah.com

**United Kingdom (Northern Ireland)**  
Tel: +44 3308221732  
PV.XXI@elancoah.com

#### Manufacturer responsible for batch release:

Elanco France S.A.S., 26 rue de la Chapelle, 68330 Huningue, France

#### **17. Other information**

Lotilaner, a pure enantiomer from the isoxazoline class, is active against fleas (*Ctenocephalides felis* and *Ctenocephalides canis*) and ticks (*Ixodes ricinus*).

Lotilaner is a potent inhibitor of gamma-aminobutyric acid (GABA)-gated chloride channels, resulting in rapid death of ticks and fleas. In *in vitro* studies, the activity of lotilaner against some arthropod species was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin).

For fleas, the onset of efficacy is within 12 hours of attachment for one month after product administration. Fleas on the animal prior to administration are killed within 8 hours.

For ticks, the onset of efficacy is within 24 hours of attachment for one month after product administration. Existing ticks on the animal prior to administration are killed within 18 hours.

The veterinary medicinal product kills existing and newly emerged fleas on cats before they can lay

eggs. Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the cat has access.